How Much Melatonin Is Too Much? Safe Doses, Overdose Signs, and Better Alternatives

What Is a Safe Melatonin Dose for Adults?

The physiologically effective dose of melatonin for sleep onset is far lower than most over-the-counter products suggest. A dose of 0.5 mg to 3 mg, taken 30 to 60 minutes before the target bedtime, raises blood melatonin levels into the range that naturally occurs during nighttime darkness, roughly 100 to 200 picograms per milliliter. A 2001 pharmacokinetic study in the Journal of Clinical Endocrinology and Metabolism found that a 0.5 mg oral dose restored physiological nocturnal melatonin concentrations in elderly subjects better than a 3 mg dose, which produced supraphysiological levels.

The U.S. market routinely sells 5 mg and 10 mg tablets. Those numbers reflect retail convenience, not clinical guidance. Taking 10 mg produces blood concentrations roughly 10 to 100 times higher than the body generates on its own, and randomized controlled trial data do not show that higher concentrations produce proportionally better sleep. A 2017 meta-analysis of 19 trials published in PLOS ONE (N=1,683) found that melatonin reduced sleep onset latency by a mean of 7.06 minutes and increased total sleep time by 8.25 minutes, with no dose-response relationship above approximately 3 mg [1].

Stick with the lowest effective dose. If 0.5 mg or 1 mg fails after two weeks of consistent use, a conversation with a sleep-medicine clinician is more productive than doubling the tablet.

How Much Melatonin Is Too Much: Defining the Threshold

"Too much" has two practical definitions: the dose that produces adverse effects and the dose that exceeds what any published trial supports as beneficial. Both thresholds sit below 10 mg for most adults.

Short-term adverse effects at doses above 5 mg include next-morning drowsiness, headache, dizziness, nausea, and mild hypothermia. These are dose-dependent. A case series reviewed by the National Institutes of Health MedlinePlus documents that accidental ingestions of 30 mg to 100 mg in adults produced prolonged sedation and disorientation but no fatal outcomes.

The Poison Control Center data are instructive here. The American Association of Poison Control Centers logged a 530% increase in melatonin ingestion calls between 2012 and 2021, with pediatric cases accounting for the majority. A 2022 report in MMWR Morbidity and Mortality Weekly Report documented 260,435 pediatric melatonin ingestion calls over that decade, with 4,097 hospitalizations and 287 intensive-care admissions [2]. Most pediatric cases involved products labeled 5 mg or higher.

The HealthRX Melatonin Dose Decision Framework:

| Goal | Recommended Starting Dose | Maximum Supported Dose | Notes | |---|---|---|---| | Jet lag (eastward travel) | 0.5 mg at destination bedtime | 3 mg | Start night of arrival | | Delayed sleep-wake phase disorder | 0.5 mg, 5-6 hours before natural sleep onset | 3 mg | Timing matters more than dose | | General sleep-onset insomnia | 1 mg, 30-60 min before bed | 5 mg | CBT-I preferred first-line | | Shift work | 1-3 mg at new sleep time | 5 mg | Use consistently on days off | | Children (with physician oversight) | 0.5-1 mg | 3 mg | AAP advises physician guidance |

Any use exceeding 10 mg per night falls outside what current randomized trial data support.

Is Melatonin Safe Long Term?

Melatonin appears safe for short-to-medium-term use, but trials extending beyond six months are scarce. A 2020 systematic review in Sleep Medicine Reviews examining 18 randomized controlled trials found no significant safety signals at doses of 2 to 5 mg over periods up to six months. Adverse event rates in melatonin groups did not differ statistically from placebo groups.

The concern with long-term high-dose use is hormonal. Melatonin is not an inert molecule. It interacts with the hypothalamic-pituitary axis and may suppress endogenous melatonin synthesis with prolonged supraphysiological dosing. A rodent study published in the Journal of Pineal Research showed that chronic exogenous melatonin administration reduced endogenous pineal production, though direct translation to humans requires caution. Human data on this specific question are limited to case reports rather than controlled trials.

Three additional concerns apply:

Reproductive hormones. Melatonin receptors are present on ovarian granulosa cells and Leydig cells in the testes. High-dose melatonin could theoretically interfere with luteinizing hormone release. Women trying to conceive should discuss use with their physician before starting any melatonin regimen above 1 mg.

Drug interactions. Melatonin is metabolized by CYP1A2. Fluvoxamine, a strong CYP1A2 inhibitor, can increase melatonin blood levels 17-fold [3]. Caffeine is also a CYP1A2 substrate and may compete for the same pathway.

Supplement purity. The FDA regulates melatonin as a dietary supplement, not a drug, which means no pre-market efficacy or purity review occurs. A 2017 analysis in the Journal of Clinical Sleep Medicine tested 31 commercial melatonin supplements and found the actual melatonin content ranged from 83% below to 478% above the labeled dose. Serotonin was detected in 26% of samples at potentially pharmacologically active concentrations.

For most healthy adults, nightly use at 0.5 to 3 mg appears reasonable for up to six months. Beyond that, a physician-supervised approach, with periodic trials of discontinuation, is appropriate.

Melatonin vs. Ambien: Is Ambien Addictive, and Can You Take It Every Night?

Zolpidem (Ambien) is a non-benzodiazepine GABA-A receptor agonist approved by the FDA in 1992. It is classified as a Schedule IV controlled substance under the Controlled Substances Act, which reflects a recognized potential for dependence. That classification puts it in the same category as benzodiazepines, though its receptor selectivity was initially expected to reduce addiction risk.

That expectation has not fully held. Physical dependence on zolpidem can develop within two weeks of nightly use. A 2019 review in the Journal of Addiction Medicine found that roughly 40% of patients who used zolpidem nightly for more than four weeks experienced rebound insomnia on discontinuation, a hallmark of dependence. Tolerance also develops; the 10 mg dose that produced adequate sleep in week one may produce inadequate sleep by week six.

Can you take Ambien every night? The FDA-approved prescribing information recommends zolpidem for short-term use only, generally 7 to 10 days, with a maximum of 35 days for the extended-release formulation [4]. Long-term nightly use is off-label and carries documented risks: next-day cognitive impairment, increased fall risk in adults over 65, complex sleep behaviors including sleepwalking and sleep-driving, and withdrawal seizures on abrupt discontinuation of high doses.

Melatonin carries none of those risks at physiological doses. It produces no receptor downregulation, no withdrawal syndrome, and no Schedule IV classification. The trade-off is that melatonin is substantially less potent than zolpidem for severe insomnia. If someone has been awake for 48 hours, 1 mg of melatonin is unlikely to resolve the problem.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder in adults" [5]. Both zolpidem and melatonin are positioned as adjuncts when behavioral therapy alone proves insufficient.

Why Does Trazodone Cause Grogginess?

Trazodone is an antidepressant prescribed off-label for insomnia at doses well below its antidepressant range, typically 25 mg to 100 mg versus the 150 mg to 400 mg range used for depression. The grogginess many patients report the morning after a trazodone dose comes from two distinct pharmacological mechanisms.

First, trazodone is a potent antagonist at histamine H1 receptors. H1 blockade produces sedation, the same mechanism that makes older antihistamines like diphenhydramine drowsy-making. This effect is dose-dependent but does not fully resolve by morning for everyone.

Second, trazodone's elimination half-life ranges from 5 to 9 hours [6]. A dose taken at 10 p.m. still has measurable serum concentrations at 7 a.m. for patients at the longer end of that half-life distribution. The result is residual sedation that impairs driving, reaction time, and cognitive function for 2 to 4 hours after waking.

A 2014 pharmacokinetic review in the Journal of Clinical Pharmacology confirmed that trazodone's active metabolite, m-chlorophenylpiperazine (mCPP), contributes to residual next-day effects through its own serotonergic activity. Patients who metabolize trazodone slowly via CYP3A4, which is inhibited by many common drugs including azole antifungals and certain macrolide antibiotics, face disproportionately higher next-morning plasma levels.

Practical strategies to reduce trazodone grogginess include taking the dose 90 minutes before the target sleep time rather than immediately before bed, starting at 25 mg and titrating only if needed, and avoiding grapefruit juice, which also inhibits CYP3A4.

Compared to zolpidem, trazodone carries no controlled-substance classification, no risk of complex sleep behaviors, and lower addiction liability. Compared to melatonin, trazodone is a prescription drug with a clinically meaningful side-effect profile. The appropriate choice depends on insomnia severity, comorbidities, and concomitant medications.

Signs You Have Taken Too Much Melatonin

Recognizing excess melatonin is straightforward if you know what to look for. Most symptoms appear within 30 to 90 minutes of ingestion and resolve within 6 hours.

Mild-to-moderate excess (above 5-10 mg):

• Persistent drowsiness extending more than 2 hours past target sleep time
• Vivid or disorienting dreams
• Headache behind the eyes
• Nausea without vomiting
• Mild drop in core body temperature, perceived as unusual chills

High-dose ingestion (above 30 mg):

• Prolonged sedation beyond 8 hours
• Disorientation or confusion on waking
• Blood pressure changes (melatonin has mild vasodilatory effects via MT1/MT2 receptor activation)
• Possible exacerbation of autoimmune conditions due to immune-modulatory effects

If a child ingests an unknown quantity from an unsecured product, call Poison Control at 1-800-222-1222 immediately. The 2022 MMWR report referenced above found that 94.3% of pediatric melatonin poisoning cases involved children under 5 years old who accessed unsecured supplements [2].

Who Should Not Take Melatonin

Certain populations face elevated risk from melatonin at any dose above 0.5 mg.

Pregnant individuals. Melatonin crosses the placenta and the fetal blood-brain barrier. Animal data published in the American Journal of Obstetrics and Gynecology show that supraphysiological melatonin exposure in late gestation alters fetal hypothalamic development. Human data are insufficient to confirm safety, and melatonin is not recommended during pregnancy except under direct physician supervision.

People with autoimmune conditions. Melatonin stimulates Th1 immune responses and increases natural killer cell activity. A review in Clinical Endocrinology found that high-dose melatonin could worsen autoimmune disorders including rheumatoid arthritis and multiple sclerosis in some patients.

People taking anticoagulants. Melatonin has modest antiplatelet activity. Concurrent use with warfarin may raise INR in susceptible individuals. A case series in the Annals of Pharmacotherapy documented clinically significant INR elevation in two patients after starting 2 mg nightly melatonin while on stable warfarin doses.

Children and adolescents without physician oversight. The pediatric brain is still developing melatonin receptor density through puberty. The AAP's 2020 guidance states that melatonin use in children should follow physician guidance and that doses above 1 to 3 mg are rarely appropriate outside specific diagnoses such as autism spectrum disorder or ADHD-related sleep problems.

Better First-Line Options for Chronic Insomnia

If melatonin at low doses has not resolved insomnia after four weeks of consistent use, escalating to higher doses is rarely the answer. Chronic insomnia disorder, defined as difficulty initiating or maintaining sleep at least three nights per week for at least three months, affecting daytime function, affects approximately 10% to 15% of American adults [7].

Cognitive behavioral therapy for insomnia (CBT-I) produces remission in 70% to 80% of patients with chronic insomnia in controlled trials, with effects that persist at 12-month and 24-month follow-up, a durability that no sleep medication has matched [8]. CBT-I includes sleep restriction therapy, stimulus control, cognitive restructuring, and sleep hygiene optimization. Digital CBT-I programs, including FDA-cleared prescription software such as Somryst, now deliver this treatment without requiring a therapist.

When pharmacological support is genuinely needed alongside behavioral therapy, the AASM 2017 guideline offers conditional recommendations for doxepin 3 to 6 mg, suvorexant 10 to 20 mg, and low-dose trazodone as options with better long-term safety profiles than zolpidem. Melatonin receives a conditional recommendation specifically for circadian rhythm sleep-wake disorders, not for general chronic insomnia.

The takeaway: if you are taking more than 5 mg of melatonin nightly and still not sleeping well, the dose is not the solution. The diagnosis is.